Browse Category

NASDAQ:DXCM News 8 January 2026 - 13 January 2026

DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

NEW YORK, Jan 13, 2026, 7:52 AM ET — Premarket DexCom shares climbed roughly 5% in premarket action Tuesday, buoyed by new guidance that thrust the diabetes-device company back into focus as earnings season kicks off. (Streetinsider) DexCom’s preliminary Q4 update offers investors an early glimpse at 2026 revenue growth, following a stretch where talk around guidance hurt the stock…
Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

New York, Jan 8, 2026, 15:31 (EST) — Regular session Accenture plc shares rose about 4.1% to $285.18 in afternoon trading on Thursday, after opening at $272.25 and sliding to $270.53. The stock later touched $286.53, putting it ahead of other IT-services names. Cognizant gained 2.1%, IBM climbed 2.0% and DXC added 0.9%. Accenture said it has invested, through Accenture…

Stock Market Today

  • PROCEPT BioRobotics Shares Show Mixed Performance Amid Valuation Gap
    January 27, 2026, 11:50 PM EST. PROCEPT BioRobotics (PRCT) shares rose 3.95% in one day but face a 57.81% decline over 12 months, highlighting conflicting short- and long-term momentum. Trading at $30.78, the stock is well below its $50.73 estimated fair value based on expected revenue growth and margin expansion from its HYDROS robotic system. However, its price-to-sales ratio of 5.7x exceeds industry and peer averages, signaling potential valuation risk. Investors should watch adoption rates and supply chain factors closely as these will impact future earnings and valuation. The stock's mixed returns and elevated ratios prompt caution despite promising underlying growth prospects in the healthcare robotics space.
Go toTop